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b2-Agonists are effective bronchodilators due primarily to their abil-
ity to relax airway smoothmuscle (ASM). They exert their effects via
their binding to the active site of b2-adrenoceptors on ASM, which
triggers a signaling cascade that results in a number of events, all of
which contribute to relaxation of ASM. There are some differences
between b2-agonists. Traditional inhaled short-acting b2-agonists
albuterol, fenoterol, and terbutaline provide rapid as-needed symp-
tom relief and short-term prophylactic protection against broncho-
constriction induced by exercise or other stimuli. The twice-daily
b2-agonists formoterol and salmeterol represent important advan-
ces. Their effective bronchodilating properties and long-term im-
provement in lung function offer considerable clinical benefits to
patients.More recently, a newerb2-agonist (indacaterol) with a lon-
ger pharmacodynamic half-life has been discovered, with the hopes
of achieving once-daily dosing. In general, b2-agonists have an ac-
ceptable safety profile, although there is still controversy as to
whether long-acting b2-agonists may increase the risk of asthma
mortality. In any case, they can induce adverse effects, such as in-
creasedheart rate,palpitations, transientdecrease inPaO2, andtremor.
Desensitization of b2-adrenoceptors that occurs during the first few
days of regular use of b2-agonist treatment may account for the com-
monlyobservedresolutionof themajorityof theseadverseeventsafter
the first few doses. Nevertheless, it can also induce tolerance to bron-
choprotective effects of b2-agonists and has the potential to reduce
bronchodilator sensitivity to them. Some novel once-daily b2-agonists
(olodaterol, vilanterol, abediterol) are under development, mainly in
combination with an inhaled corticosteroid or a long-acting antimus-
carinic agent.
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Yamanashi and colleagues isolated ephedrine, a nonselective
a-adrenoceptor (AR) and b-AR agonist, in 1887 from the Chi-
nese herb ma huang, which has been used for over 5,000 years to
treat asthma, hay fever, and bronchitis (1). At the beginning of the
twentieth century, epinephrine was introduced into clinical prac-
tice and was administered by the subcutaneous route for the treat-
ment of acute asthma. However, the history of b2-agonists really
started with the discovery of albuterol by Sir David Jack and
colleagues (1). The early b2-agonists, albuterol, fenoterol, and ter-
butaline, have a short duration of action, typically 4 to 6 hours, and
are referred to as short-acting b2-agonists (SABAs). Consequently,
the next advance was the development of the longer-acting agents
salmeterol and formoterol, referred to as long-acting b2-agonists
(LABAs), whose duration of action is approximately 12 hours,
which made their use more appealing (1). More recently, several
newer b2-agonists with longer pharmacodynamic half-lives have
been discovered and called ultra-LABAs, of which indacaterol is
the archetype and already marketed as a once-daily treatment (2).
MECHANISM OF ACTION
b2-Agonists are effective bronchodilators due primarily to their
ability to relax airway smooth muscle (ASM). They exert their
effects via their binding to the active site of b2-ARs, which are
densely located on ASM. The presumed cellular mechanism of
action involves the canonical signaling pathway via activation of
adenylyl cyclase (AC) and generation of intracellular cAMP,
which in turn can activate the effector molecules cAMP-
dependent protein kinase A (PKA) and Epac, a Rap1 guanine
nucleotide exchange factor (3) (Figure 1). PKA phosphorylates
key regulatory proteins involved in the control of ASM tone, Epac
induces ASM relaxation in a largely PKA-independent manner
through down-regulation of Rho, and cAMP results in sequestra-
tion of intracellular Ca21, leading to relaxation of the ASM (4).
However, it has become increasingly clear that signaling through
adenylyl cyclase–coupled pathways is considerably more complex
and sophisticated than was previously considered, although there
is still little known regarding these pathways in airway cells (4).
PHARMACOKINETICS
When b2-agonists are administered by inhalation, a route that
enables delivery of low doses of an aerosolized drug to its site of
action for a localized effect and, consequently, a rapid clinical
response with less systemic side effects, the therapeutic effects
depend on local tissue concentrations that may not be directly
related to plasma drug concentrations. In fact, the peak plasma
b2-agonist concentration is able to account for only a small frac-
tion of the decrease in airway resistance (5), and even though very
little of the inhaled dose of a b2-agonist reaches the airways, this
small amount produces effective bronchodilatation (5).
b2-Agonists are eliminated via the systemic circulation. Sys-
temic drug concentrations will in general result from absorption
of drug across the pulmonary vascular bed and also via the gas-
trointestinal tract; a portion of an inhaled drug is always swal-
lowed through the oropharynx and can thus reach the systemic
circulation from the gastrointestinal tract (5). Systemic absorp-
tion of the drug can cause unwanted side effects.
PHARMACODYNAMICS
b2-Agonists act by mimicking some of the effects of epinephrine
at several levels: (1) inhibitory action on ASM; (2) stimulation of
the heart, leading to increased heart rate, contraction, and con-
duction; (3) inhibition of the release of mediators from mast cells;
(4) metabolic actions (e.g., glycogenolysis in liver and skeletal
muscle, resulting in an increase in glucose); (5) endocrine actions
(increasing insulin and glucagon release); and (6) prejunctional
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action on parasympathetic ganglia, increasing or decreasing ace-
tylcholine release (1). In addition to their main bronchodilator
effect, this class of drugs also protects against the actions of
bronchoconstrictor stimuli.
CLINICAL USE
SABAs are currently only used as rescue medications for ob-
structive lung diseases, because their short half-life limits their
use as maintenance treatments. On the contrary, LABAs and
ultra-LABAs provide sustained bronchodilation and, although
they areunable to influence the accelerated decline in lung function
characteristic of chronic obstructive pulmonary disease (COPD),
at least in terms of clinically noticeable changes, they offer greater
convenience for patients with COPD. Actually, they induce signif-
icant improvements in FEV1, reduce dynamic hyperinflation, and
improve exercise tolerance (1, 2), causing improvements in dysp-
nea and health-related quality of life (HRQoL) (1, 2). Moreover,
they reduce the frequency of COPD exacerbations (6) and offer
a potential survival advantage (7). On the contrary, in asthma the
safe use of LABA can only be assured if used in combination with
an inhaled corticosteroid (ICS) in adequate dosage, preferably in
a single inhaler device (8). In fact, by providing effective symptom
relief and improvement in lung function, LABAs may mask un-
derlying inflammation that may develop or increase if the dose of
ICS is inadequate, leading to more exacerbations and even mor-
tality from uncontrolled asthma, as documented by the Salmeterol
Multicenter Asthma Research Trial (SMART) (9).
DOSING STRATEGIES
The large interpatient and interstudy variability in FEV1 with
bronchodilators makes determination of optimum doses difficult.
In particular, the low signal-to-noise ratio inherent in the mea-
surement of FEV1 and the poor precision of the conventional
methodologies do not offer a rigorous basis for identification of
the minimally effective, optimal, or maximum doses. To overcome
this limitation, it has been suggested to use a model-based ap-
proach that includes a pooled analysis of study-level data to
characterize the bronchodilatory dose response of the examined
agent and nonlinear mixed-effects analysis of patient-level data
to characterize the effect of baseline covariates (10). However,
regulatory authorities do not yet accept model-based approaches
(11).
Ideally, b2-agonists should be used at the lowest dose and
frequency required. However, patients with severe COPD need
high doses to achieve optimum bronchodilatation (11). High-dose
b2-agonists should also be considered for patients with acute
exacerbations of COPD, although there is a great deal of con-
troversy regarding the timing and optimal dose (12). The duration
of the bronchodilator effect of inhaled b2-agonists is decreased in
COPD exacerbation (12). To overcome the reduced functional
half-life of b2-agonists, it has been suggested not only to use
larger-than-usual doses that are sometimes necessary to relieve
airway obstruction but also to shorten the posologic interval (12).
However, this therapeutic approach may expose patients to sys-
temic concentrations of the drug that are too high. The treatment
of acute asthma includes the repetitive administration of inhaled
SABAs, although it has been suggested that high-dose formoterol
is well tolerated and provides rapid and effective bronchodila-
tion, similar to high-dose SABAs, and allows less repeated rescue
medication (13).
COST-EFFECTIVENESS
Because of differing health policies, costs, health insurance issues,
pharmaceutical/commercial aspects, and prescribers’ and patients’
preferences across different countries worldwide, it is difficult to
assess the cost-effectiveness of b2-agonists. The currently available
economic evaluations indicate differences in cost-effectiveness be-
tween bronchodilators, but there is a great need to improve the
consistency with respect to study methodology and choice of com-
parator (14). Even taking into account all these limitations, com-
pared with albuterol, the use of formoterol as rescue medication
in patients with asthma produces statistically significant improve-
ments in effectiveness, less reliever and maintenance medication
use, and reduced healthcare resource use, with no increase or
a limited increase in healthcare cost (15). Moreover, an old cost-
effectiveness analysis of formoterol versus salmeterol in patients
with asthma showed that there was no evidence to suggest that
either treatment was more cost effective than the other (16). In
COPD, the available economic evidence indicates that salmeterol
may be less cost-effective than tiotropium bromide, a long-acting
antimuscarinic agent (LAMA), in several specific settings, but
there is considerable uncertainty around this finding (17). A recent
cost-usefulness analysis of indacaterol in Germany showed that
indacaterol 150 mg is better than (lower total costs and better out-
comes) tiotropium bromide or salmeterol. An alternative analysis
comparing indacaterol 300 mg (maximum dose) against tiotropium
showed an incremental cost-effectiveness ratio of approximately
€28,300 per quality-adjusted life-year (18).
COMBINATION THERAPY
Combination therapy with an LABA and an ICS is considered an
important approach for treating patients with asthma (8) and
patients with severe COPD who have frequent exacerbations (19).
In patients with asthma who have suboptimal control on low-dose
ICS monotherapy, the LABA/ICS combination is a little more
effective in reducing the risk of exacerbations requiring oral
corticosteroids, improving lung function and symptoms, and de-
creasing use of rescue b2-agonists than a higher dose of ICS (20).
In adults with asthma who are symptomatic on low to high doses
of ICS monotherapy, the addition of an LABA at licensed doses
reduces the rate of exacerbations requiring oral steroids, im-
proves lung function and symptoms, and modestly decreases use
of rescue b2-agonists (21). In children, the effects of this treatment
option are much more uncertain (21).
Figure 1. Mechanism of action of b2-agonists (based on information
from Reference 3). AC ¼ adenylyl cyclase; b2R ¼ b2 receptor; cAMP ¼
cyclic adenosine monophosphate; Epac ¼ exchange protein directly
activated by cAMP; Gs ¼ stimulatory G-protein; HSP-20 ¼ heat shock–
related protein 20; MLCK ¼ myosin light chain kinase; MLC-P ¼ myosin
light chain phosphatase; PDE ¼ phosphodiesterase; PKA ¼ protein kinase
A; SR/RyR Ca21 ¼ sarcoplasmic reticular ryanodine Ca21 channel.
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In COPD, the addition of LABA to ICS leads to significantly
greater improvements in lung function, exacerbations, health
status, and breathlessness and a reduction in all-cause mortality
compared with monotherapy with the component drugs, although
combination treatments may differ with regard to specific out-
comes (22). Interestingly, the Toward a Revolution in COPD
Health (TORCH) study showed that the mortality benefit is en-
tirely due to the LABA rather than the ICS component (7).
Several studies demonstrate that there are a number of added
benefits in using combinations of b2-agonists and antimuscarinic
agents. In particular, LABA/LAMA combination seems to play
an important role in maximizing bronchodilation (23). Although
improving lung function is a key goal of COPD pharmacotherapy,
its measurements alone may not adequately reflect the overall
health status of the patient. However, LABA/LAMA combina-
tion therapies demonstrate greater improvements in patient-
centered outcomes such as dyspnea, symptoms, rescue medication
use, and quality of life than individual drugs used alone (24).
MEASURING EFFECTS AND OUTCOMES
In COPD, FEV1 is used in diagnosis and staging, arterial blood
gases are useful in defining respiratory failure, and dynamic hy-
perinflation helps to explain exertional dyspnea (25). Therefore,
to assess the impact of a b2-agonist in COPD, it is necessary to
explore lung function parameters other than FEV1, for example:
FVC and IC to TLC ratio, measures of dyspnea, functional status,
health status and HRQoL, exercise tolerance, and breathlessness
after exercise (26). The frequency of exacerbations is another im-
portant outcome that should be considered in COPD (26). Unfor-
tunately, in contrast to monitoring lung function, there is no gold
standard for measuring symptoms such as dyspnea, health status,
exercise capacity, physical activity, or exacerbations, because none
of the available methods is optimal in all regards (26).
Measuring effects and outcomes of b2-agonists as monother-
apy in asthma is even more complicated. The primary goal of
asthma therapy is to achieve and maintain control of disease, as
defined by a global assessment of symptoms, reliever use, lung
function, and the frequency/severity of exacerbations (8). The
impact of b2-agonists on lung function must always be assessed.
However, traditional measures of lung function are an impor-
tant indicator of severity but insufficient as an index of asthma
control (8), and several studies have shown that LABAs might
increase the risk of exacerbations and asthma mortality when
used by patients with unstable asthma without concomitant ICS
or scheduled medical review (9, 27). Therefore, the outcomes of
interest of b2-agonists must include a composite measure incor-
porating lung function measures, symptom scores, HRQoL meas-
ures, and markers that can determine the impact of therapy on
underlying inflammation but also asthma death and hospitaliza-
tion for status asthmaticus.
ADVERSE EFFECTS
All b2-agonists can induce increased heart rate and palpitations,
because some of the b-ARs in the atria and ventricles are b2,
and thus even selective b2-agonists can provoke direct simula-
tion of the heart (1, 28). Moreover, stimulation of b2-ARs can
result in vasodilation and reflex tachycardia (1, 28).
Administration of b2-agonists can also induce a transient de-
crease in PaO2 despite concomitant bronchodilation. However,
the declines observed are small, transient, and have doubtful clinical
significance (1, 29).
b-AR stimulation in the liver induces glycogenolysis and raises
blood sugar levels (30). Therefore, b2-agonists should always be
used with caution in patients with diabetes because of the risk of
ketoacidosis. Hypokalemia is also a risk with b2-agonist treat-
ment (31) because of stimulation in skeletal muscle of the Na1,
K1-ATPase-driven pump coupled to b-ARs (1). This increases
the ability of the Na1, K1 pump to push Na1 out of the cell and
facilitate intracellular accumulation of K1, thereby lowering
plasma levels. Such hypokalemia may precipitate arrhythmias;
hence, the use of b2-agonists is linked to an increased incidence
of tachyarrhythmia (1). Dose-related tremor is one of the most
characteristic adverse effects after administration of b2-agonists
as they can directly stimulate b-ARs on skeletal muscle (32).
An early explanation of the tremor was that b2-AR shortens the
active state of skeletal muscle, which leads to incomplete fusion
and reduced tension of tetanic contractions. More recently,
tremor has been correlated closely with hypokalemia. Desensi-
tization of b2-ARs that occurs during the first few days of reg-
ular use of b2-agonist treatment may account for the commonly
observed resolution of the majority of these adverse events after
the first few doses (1).
Prolonged or repeated use of b2-agonists leads to loss of
some of their effects, a pervasive phenomenon termed tachy-
phylaxis, refractoriness, or desensitization (1). In effect, regular
b2-agonist use can induce tolerance to their bronchoprotective
effects and has the potential to reduce bronchodilator sensitivity
to b2-agonists (33). Tolerance to rescue SABA therapy and
increased sensitivity to bronchoconstricting stimuli can lead to
decreased asthma control, necessitating hospitalization for fur-
ther management (34). Tolerance to bronchoprotective effects
of LABAs has been demonstrated against spasmogens and ex-
ercise, although there is still controversy as to whether LABAs
may increase the risk of asthma mortality (35). A study that
explored risks of death and asthma outcomes with prescription
of LABAs, SABAs, or ICSs in general practice reported no
major statistically significant increases in the risks of outcomes
with LABAs compared with ICSs in patients with similar expo-
sure characteristics (36). Furthermore, the relative rates of these
outcomes did not vary statistically with changes in exposure
between LABA and ICS. In fact, the relative rates in heavy
long-term users were 1.9 for all-cause mortality and 3.0 for asthma
death with SABA; 1.4 and 1.6, respectively, with LABA; and 1.7
and 2.2, respectively, with ICS (36).
It is noteworthy that stepping down treatment with LABAs
after the establishment of acceptable asthma control results in
the patient’s asthma symptoms becoming less well controlled (37).
In any case, evidence from randomized clinical trials, meta-analysis
of randomized clinical trials, and observational studies, although
limited by low statistical power, have indicated that in patients with
asthma, the use of combination therapy (LABA plus ICS) is asso-
ciated with a decreased risk of serious asthma-related events (38).
This is particularly true when the concomitant use of LABA plus
ICS can be reasonably assured (combined in a single inhaler) (38).
In patients with COPD, the long-term use of b2-agonists results
in sustained improvements in bronchodilatory activity, with no in-
dication of development of tolerance even with the ultra-LABA
indacaterol (39). Moreover, a pretreatment with a conventional
dose of formoterol or salmeterol does not preclude the ability of
inducing a further bronchodilation with albuterol (40).
SAFETY SYSTEMS
Adverse effects of b2-agonists are greatest when such drugs are
administered orally or parenterally (1). The use of inhaled aero-
sols allows selective treatment of the lungs directly by achieving
high drug concentrations in the airway while reducing adverse
effects by minimizing systemic drug levels (39). Direct delivery
to the lungs also permits a more rapid bronchodilation in response
to b2-agonists.
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b2-Agonists can be administered using pressurized metered-
dose inhalers (pMDIs), breath-actuated pMDIs, dry powder
inhalers, nebulizers, or soft mist inhalers. Consequently, under-
standing the possible diverse impact of different modes of ad-
ministration of b2-agonists on adverse events is mandatory. The
choice of the device used to deliver a b2-agonist is crucial in
determining its pharmacokinetic profile. Increased fine particle
mass and lung deposition result in greater systemic exposure,
whereas oropharyngeal deposition becomes greater as particle
size increases above 6 mm (41). Adverse effects appear to be more
common with nebulizer use than with the use of a pMDI, probably
because nebulizers deliver a larger systemically absorbed dose
(42), whereas deposition of aerosols in the deeper part of the
lungs (i.e., the alveolar region) results in an increased propor-
tion of the drug reaching the systemic circulation if delivered
doses are not optimized to minimize systemic exposure (43).
Because adverse events with inhaled drugs can be device-
dependent, the consequence of a change of the inhalation device
should be considered both from an efficacy and a safety stand-
point, even when using the same starting dose (32).
GUIDELINES
The strategy document of the Global Initiative for Chronic Ob-
structive Lung Disease (19) recommends the use of long-acting
bronchodilators in all patients with COPD. It does not prefer
b2-agonists to antimuscarinic agents, but it highlights that the
choice depends on the availability of medication and the patient’s
response. Based on efficacy and side effects, inhaled bronchodi-
lators are preferred over oral agents. b2-Agonists can be com-
bined with antimuscarinic agents if symptoms are not improved
with single agents. They can be combined with ICSs if patients
with FEV1 less than 50% of predicted and/or frequent exacerba-
tions are not adequately controlled by long-acting agents, or with the
phosphodiesterase-4 inhibitor roflumilast if patients present chronic
bronchitis, FEV1 less than 50% of predicted, and frequent exacer-
bations that are not adequately controlled by long-acting agents.
In contrast, the Global Initiative for Asthma executive sum-
mary (8) recommends never using LABAs as monotherapy for
the treatment of subjects with asthma as they may put patients at
risk of exacerbations. LABAs are most effective when combined
with ICSs, and this combination therapy is the preferred treatment
when a medium dose of ICS alone fails to achieve control of
asthma. SABAs are the medications of choice for quick relief of
bronchospasm during acute exacerbations of asthma and for the
pretreatment of exercise-induced bronchoconstriction. They
should be used only on an as-needed basis at the lowest dose
and frequency required.
FUTURE DEVELOPMENTS
In addition to indacaterol, several once-daily LABAs are currently
undergoing development, but detailed information on these drugs is
still scarce (1, 44, 45). Olodaterol (BI1744 CL, Boehringer Ingelheim,
Ingelheim, Germany) and vilanterol (GSK642444, GlaxoSmithKline,
London, UK) are two once-daily LABAs already in phase III
clinical trials, whereas abediterol (LAS10097, Almirall, Barce-
lona, Spain, and Forest Laboratories, New York, NY), AZD3199
(AstraZeneca, Lund, Sweden), and PF-610355 (Pfizer, New York,
NY) are in an earlier phase of clinical development; it is likely
that the last two agents have been discontinued for strategic and
regulatory reasons. Figure 2 shows the chemical structures of
these once-daily LABAs. They are single enantiomers of the
(R)-configuration. Table 1 illustrates their main pharmacological
properties. All have a near full-agonist profile at human b2-AR.
This seems to be an important pharmacological property, because
high-efficacy agonists may cause a greater loss of adrenoceptors
than low-efficacy agonists but are more tolerant to this, as they
have “spare receptors” effect, resulting in a loss in potency but
not necessarily any loss of maximal effect and are therefore less
sensitive to loss of receptors through desensitization (46).
It is still unclear why LABAs are able to cause such long bron-
chodilation, and several contrasting hypotheses have been for-
mulated. The debate around the mechanism for the long clinical
duration of action exhibited by inhaled LABAs has been ongoing
since the discovery and clinical use of salmeterol and formoterol in
the early 1990s. Apparently, slow receptor dissociation is not a key
factor in the duration of action of inhaled once-daily LABAs, and
partitioning of the drug into lipophilic compartments after inhala-
tion is the key determinant of their long duration of action (47). It
has been suggested that in ASM, small lipid rafts (50–100 nm), the
areas of the plasma membranes where b2-ARs are held together
in close contact with signaling and effectors molecules, might play
a role in long duration of action of indacaterol (48). Indacaterol
has twofold higher affinity for raft microdomains compared with
salmeterol, and this might contribute to the difference in duration
of action (48).
Also, vilanterol is a highly lipophilic molecule partitioning in-
to cell membrane and forming depots of drug, but it is not pos-
sible to rule out that vilanterol binds directly to an anchored
binding site within the b2-AR (49). On the contrary, olodaterol
has a moderate propensity to accumulate in the lipid bilayer, and
Figure 2. Chemical structures of salmeterol, formoterol, inda-
caterol, and emerging once-daily long-acting b2-agonists.
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therefore the microkinetic theory cannot be dismissed fully (50).
Moreover, a second aspect, namely, the tight binding of olodaterol
to the human b2-AR and formation of the ternary complex, was
identified. It has been suggested that this complex, with a dissoci-
ation half-life of 18 hours, indeed might be a rationale for the 24-h
duration of action of olodaterol (50), but this contrasts with the
view that slow receptor dissociation is not a key factor in the
duration of action of inhaled once-daily LABAs (47).
However, regardless of the mechanism that explains its dura-
tion of action, olodaterol induces bronchodilation up to 24 hours
postdosing in patients with COPD (51) and protects against
methacholine-induced bronchoconstriction for up to 32 hours
after the administration of a single dose in patients with inter-
mittent asthma (52), with a clear dose–response relationship.
Vilanterol produces a dose-dependent rapid bronchodilation
in patients with COPD, which is maintained over 24 hours after
chronic administration, with a safety and tolerability profile sim-
ilar to placebo (53). It results in prolonged bronchodilation of at
least 24 hours with good tolerability in patients with asthma
receiving ICSs (54), and evidence suggests no advantage over
a 24-hour period of vilanterol twice daily versus once-daily dosing
for the same total daily dose (55).
Abediterol elicits rapid bronchodilation (5 min after dosing)
that is faster and longer lasting than salmeterol 50mg twice daily (45).
Fixed-dose combination formulations containing a novel once-
daily LABA with LAMA are being developed by a number of
companies. Indacaterol/glycopyrroniumbromide (QVA149,Novartis,
Basel, Switzerland), olodaterol/tiotropium bromide (Boehringer
Ingelheim), and vilanterol/umeclidinium bromide (GlaxoSmithKline)
are in advanced development for the treatment of COPD and dem-
onstrate significant broncholytic effects (1, 2, 44). Other companies
are combining formoterol with aclidinium or glycopyrronium,
but these combinations have 12-hour duration of action (45).
Fixed dose combinations of novel ultra-LABAs and ICSs are
also under development, including vilanterol/fluticasone furoate
(GlaxoSmithKline), which is in phase III clinical trials that involve
both patients with asthma and patients with COPD. It has a good
safety and tolerability profile and improves lung function compared
with placebo in patients with COPD (56) and provides significant
bronchoprotection against the early asthmatic response at the trough
of dosing (i.e., 23 h post last dose) in subjects with mild asthma (57).
Indacaterol/mometasone (QMF149, Novartis) is in phase II clinical
trials, although limited clinical data are available (45).
Author disclosures are available with the text of this article at www.atsjournals.org.
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Action (min) Referenceb1 b2
Albuterol 5.39 6 0.06 6.12 6 0.09 47 6 1 58
1:27 49
6.25 6 0.04 11.0 6 4.0 14.6 6 3.7 60
Salmeterol 6.11 6 0.09 9.19 6 0.12 38 6 1 58
1:525 19 6 5 230 6 55 59
41 6 0.01 1:3,000 49
9.61 6 0.03 1:1,259 61
6.14 6 0.02 9.24 6 0.08 8.3 6 0.8 .720 60
Formoterol 6.12 6 0.09 7.84 6 0.05 90 6 1 58
95 6 0.04 1:150 49
8.05 6 0.02 1:166 61
6.07 6 0.04 8.29 6 0.03 100 6 3 1:13 6 6 1 76 6 14 59
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